Purpose There is an increased interest in the benefits of conjugated a-linolenic acid (CLNA) on obesity-related complications such as insulin resistance and diabetes. The aim of the study was to investigate whether a 1 % dietary supplementation of mono-CLNA isomers (c9-t11-c15-18:3 ? c9-t13-c15-18:3) improved glucose and lipid metabolism in neonatal pigs. Methods Since mono-CLNA isomers combine one conjugated two-double-bond system with an n-3 polyunsaturated fatty acid (PUFA) structure, the experimental protocol was designed to isolate the dietary structural characteristics of the molecules by comparing a CLNA diet with three other dietary fats: (1) conjugated linoleic acid (c9-t11-18:2 ? t10-c12-18:2; CLA), (2) non-conjugated n-3 PUFA, and (3) n-6 PUFA. Thirty-two piglets weaned at 3 weeks of age were distributed among the four dietary groups. Diets were isoenergetic and food intake was controlled by a gastric tube. After 2 weeks of supplementation, gastro-enteral (OGTT) and parenteral (IVGTT) glucose tolerance tests were conducted. Results Dietary supplementation with mono-CLNA did not modify body weight/fat or blood lipid profiles (p [ 0.82 and p [ 0.57, respectively) compared with other dietary groups. Plasma glucose, insulin, and C-peptide responses to OGTT and IVGTT in the CLNA group were not different from the three other dietary groups (p [ 0.18 and p [ 0.15, respectively). Compared to the non-conjugated n-3 PUFA diet, CLNA-fed animals had decreased liver composition in three n-3 fatty acids (18:3n-3; 20:3n-3; 22:5n-3; p \ 0.001).
Introduction
Conjugated fatty acids refer to a set of positional and geometric isomers of polyunsaturated fatty acids (PUFA) with conjugated double bonds. Conjugated linoleic acids (CLA) were first identified in the late eighties by Pariza et al. [1] . Since then, consumption of CLA was associated with weight loss [2] and improving of insulin sensitivity [3] . Another group of conjugated fatty acids recently received more attention because it combined an n-3 and a conjugated double bond: conjugated a-linolenic acids (CLNA) [4] . CLNA isomers are naturally present in plant seeds (di-CLNA) and in dairy products (mono-CLNA). Mono-and di-CLNA differ by their conjugated doublebond system: mono-CLNA has a single conjugated doublebond system at the n-5 or n-7 carbon, i.e., rumelenic acid, c9-t11-c15-18:3, whereas di-CLNA has a double conjugated double-bond system at the n-5/n-7 or n-8/n-10 carbons, i.e., a-eleostaric acid c9-t11-t13-18:3. Mono-CLNA isomers are produced by biohydrogenation of a-linolenic acid by rumen bacteria [5, 6] .
Because of the worldwide problem of obesity in children and the related health problems such as hypertension and diabetes mellitus [7] , there is an increased interest in the development of preventive and therapeutic strategies for improving insulin resistance [8] . Indeed, using antidiabetic drugs is not appropriate for treating insulin resistance in children unless there is severe glucose intolerance or diabetes, thereby finding natural strategies such as CLNA isomers is an attractive approach which deserves to be studied. Di-CLNA is able to decrease body weight [9] and fat [10, 11] , as well as increase insulin sensitivity in rodents [9, 12, 13] . Some studies also reported that either CLA [14] or n-3 PUFA [15] or the combination of the two [16] could improve glucose tolerance. Since a mono-CLNA such as c9-t11-c15-18:3 isomer combines the conjugated double-bond system of CLA and the n-3 double bond of a-linolenic acid, it is reasonable to speculate that this original fatty acid structure may provide similar or even enhanced glucose tolerance than the conjugated or n-3 double-bond structure.
Bioavailability of mono-CLNA was reported to be high in rodents. The metabolism of mono-CLNA has already been studied in different animal models excluding pigs [5, 6, 17] .
The objective of the present study was to investigate whether dietary supplementation with mono-CLNA (c9-t11-c15-18:3 ? c9-t13-c15-18:3) improves glucose metabolism in neonatal piglets. In order to isolate the role of the conjugated double-bond in combination with the n-3 PUFA structure, mono-CLNA group will be compared with three other dietary treatments: CLA isomers, non-conjugated n-3, and non-conjugated n-6 PUFAs.
Methods and materials

Animals and diets
Thirty-two Yorkshire 9 Landrace 9 Duroc piglets (females and castrated males) weaned at 3 weeks of age were separated into eight groups of four animals. To control for food intake, an esophageal gastric tube was installed into all animals as previously described by Cortamira et al. [18] . Individual adjoining metabolism cages with plastic floors allowed free movement and room temperature was kept at 27°C. At baseline, average body weight was 7.6 ± 0.4 kg. Within each group, the piglets (from the same litter) were assigned to one of four dietary treatment groups, fed entirely with a commercial diet [barley (25 %) , maize (20 %), dried whey (20 %), soybean meal (10 %), extruded soybean (8 %), and plasma protein (5 %); Table 1 ] plus either 1 % of the caloric intake of the basal diet in the form of one the following lipid emulsion of specific fatty acids: (1) synthetic mixture of two monoconjugated a-linolenic acids (c9-t11-c15-18:3 ? c9-t13-c15-18:3; CLNA); (2) mixture of two conjugated linoleic acids (c9-t11-18:2 ? t10-c12-18:2; CLA); (3) n-3 fatty acids (W3); or (4) n-6 fatty acids (W6). CLA isomers were prepared by direct dehydration of castor oil, as previously described by Trottier [19] . Mono-CLNA isomers were synthesized by alkali isomerization of a-linolenic acid. Thereafter, CLNA isomers were purified by preparative chromatography using a reverse phase column [19] . n-6 and n-3 PUFA high sources were sunflower oil (Pokonobe Industries, Montréal, QC, Canada) and linseed oil (La Maison Orphée Inc., Québec, QC, Canada), respectively. The analytical fatty acid profile of the four lipid emulsions is shown in Table 2 .
All diets were isoenergetic. The feeding regime was based on daily increment of 7.1 g feed per kg 0.75 body weight (g/kg 0.75 ) up to the target maximum daily value of 56 g/kg 0.75 . The daily intake was adjusted three times per week according to changes in body weight in order to maintain the weight stable. Basal diet was mixed with 45, 20 , and 35 % of the diet caloric intake, respectively. Dietary treatments were given during the morning meal. Before the morning meal on day 0 (before attribution of treatments) and on day 15 postweaning, body weight was measured and blood samples were collected via jugular venipuncture as previously described by Matte et al. [20] . On day 9 of the experimental protocol, a jugular catheter was installed by a non-surgical technique described by Matte et al. [21] . All animals were tested for insulin resistance by two glucose tolerance tests: a gastroenteral (OGTT) and a parenteral (IVGTT) test. Briefly, after fasting for 18 h, piglets (n = 32) were given either an oral (OGTT) or an IV (IVGTT) dose of glucose (1.0 g/kg BW) over a period of 120 min. Blood samples were collected every 30 min for 240 min (0, 30, 60, 90, 120, 150, 180, 210, and 240 min) starting after the initial glucose infusion. Blood samples were centrifuged at 3,000 rpm for 10 min at 4°C and plasma was stored at -20°C until glucose, insulin, and C-peptide analyses were performed. Two days after the first glucose test, the protocol was repeated with the other glucose test using the same animal. All animals were killed on day 17. The liver was removed and weighed, and samples were stored at -20°C for further analysis.
Throughout the experimental protocol, animals were cared for according to the recommended code of practice of Agriculture Canada [22] and the procedure was approved by the local Animal Care Committee following the guidelines of the Canadian Council on Animal Care [23] .
Biochemical analyses
Plasma glucose was measured by an enzymatic colorimetric assay (GLU GOD-PAP; Roche Diagnostics, Indianapolis, IN, USA), whereas insulin (Porcine Insulin RIA Kit PI-12K; Linco Research Inc., St Charles, MI USA) and C-peptide (Porcine C-peptide RIA kit PCP-22k; Linco Research Inc.) were assayed by commercial RIA kits. The homeostatic model assessment (HOMA2), described by Levy et al. [24] , was used to estimate insulin sensitivity (HOMA2-%S) and secretion (HOMA2-%B) from baseline plasma parameters measured during OGTT and IVGTT. The area under the curve (AUC) of glucose, insulin, and C-peptide was calculated using the trapezoidal method [25] between 0 and 210 min. Matsuda's insulin sensitivity whole-body index (ISI) was also calculated from the data generated during the OGTT [26] . An insulin sensitivity index (SI) derived from the IVGTT was calculated according to a modified method described by Bergman et al. [27, 28] .
SI was determined from 120 to 210 min of the IVGTT, i.e., after the end of the infusion to assess the deconvolution of glucose with regard to insulin after the glucose peak. Total cholesterol, triglyceride, and non-esterified fatty acid (NEFA) concentration in plasma at day 1 and day 15 were measured by the service diagnostic of the Faculty of Veterinary Medicine at the Université de Montréal (Montreal, QC, Canada). The fatty acid composition of the four diets and liver was determined by gas chromatography as previously described by Castellano et al. [29] .
Statistical analysis
According to the results obtained from similar porcine studies [15] , the calculated sample size per group (n = 8) was sufficient to detect a difference in insulin sensitivity of SFA = total saturated fatty acids, MUFA = total monounsaturated fatty acid, PUFA = total polyunsaturated fatty acids, n-3:n-6 ratio = n-3 PUFA to n-6 PUFA ratio
at least 15 % with a power of 80 % and a level of significance of 0.05. The data were analyzed by using the MIXED procedure implemented in Statistical Analysis Systems software (version 6.11 of SAS, Cary, NC, USA) [30] according to a completely randomized design with four treatments (CLNA, CLA, W3, and W6) as the main factor. The piglet was considered as the experimental unit. The following model was used:
where Y ij is the dependent variable, l is the overall mean, F i is the treatment effect, and e ij is the residual error. Comparisons among treatments were done using the following a priori contrasts (CLNA vs. W3 for CLA properties; CLNA vs. W6 for both CLA and n-3 PUFA properties; CLNA vs. CLA for n-3 PUFA properties) using a Dunnett's correction. All values are presented as mean ± SEM and differences are considered significant at p \ 0.05.
Results
Anthropometry and blood lipid parameters
Body weight of piglets pre-treatment was 7.6 ± 0.4 kg. After 2 weeks of supplementation (day 15), there was no difference (p [ 0.82) between treatments for either body weight (10.2 ± 0.4 kg) or fat content (10.0 ± 0.8 %). Total cholesterol, triglyceride, and NEFA concentrations in blood plasma for day 1 versus day 15 were 5.9 ± 0.8 versus 2.0 ± 0.1 mmol/l, 0.7 ± 0.1 versus 0.3 ± 0.1 mmol/l, and 708.3 ± 146.7 versus 769.6 ± 101.8 lmol/l, respectively. There was no difference (p [ 0.34) according to dietary treatments for these parameters.
Liver fatty acid profile
There was no significant difference (p = 0.67) in liver weight between dietary treatments. The overall organ weight was 248 ± 14 g. Evaluation of liver fatty acid composition was used as an indicator of whole-body fatty acid status modification from dietary treatments. Mono-CLNA (c9-t11-c15-18:3 ? c9-t13-c15-18:3) liver content was higher (p \ 0.001) in the CLNA diet than the other diets (0.25 vs. 0.01 g/100 g fatty acids, respectively). With regard to n-3 fatty acids, 18:3n-3, 20:3n-3, and 22:5n-3 were 20-40 % lower (p \ 0.001) in CLNA diets compared to the W3 diet. Total n-3 PUFA was also significantly lower (p \ 0.001) in the CLNA diet than the W3 diet (9.27 vs. 10.77 g/100 g fatty acids, respectively). In contrast, the proportion of arachidonic acid (20:4n-6) was 8 % higher in the CLNA group compared to the W3 group, resulting in a significantly higher total n-6 PUFA level (CLNA vs. W3, 40.61 vs. 39.52 g/100 g fatty acids, respectively).
Basal plasma glucose, insulin, and C-peptide concentration
Baseline plasma glucose, insulin, and C-peptide concentrations were evaluated before the OGTT or IVGTT load of glucose (Table 3) . A significant treatment effect was detected for fasting insulin concentration on the OGTT day (p = 0.03) and on calculated insulin sensitivity HOMA-%S but the specific contrast test did not allow discrimination between the CLNA group and the other dietary groups (p [ 0.22). There was no other treatment difference for OGTT and IVGTT (p [ 0.14; Table 3 ).
Monitoring of glucose, insulin, and C-peptide during OGTT and IVGTT AUC for glucose, insulin, and C-peptide monitored between 0 and 210 min is reported in Table 4 . Among the four dietary groups, there was no significant difference in glucose, insulin, and C-peptide monitoring over the OGTT and the IVGTT. Dietary intake did not improve the Matsuda's ISI (p = 0.71) calculated from the OGTT nor the minimal model-derived insulin sensitivity calculated from the IVGTT (SI; p = 0.51). 
Discussion
The present study aimed to investigate whether dietary supplementation with mono-CLNA improves body composition and glucose tolerance in neonatal piglets. This model was chosen because piglets represent (1) an accelerated model of postnatal development to study human neonatal nutrition and development [31] , (2) a relevant model for insulin resistance [32] , and (3) a suitable model for evaluating nutritional strategies to enhance glucose tolerance and prevent type 2 diabetes and cardiovascular diseases later in life [33] .
Body composition and blood lipids
Mono-CLNA might combine anti-obesity properties of CLA, along with those of the a-linolenic acid. There is evidence suggesting that CLA decreases body weight and fat accumulation and improves serum lipids in mice [34] , rats [35] , hamsters [36] [37] [38] , and humans [39] . Similarly, a-linolenic acid was reported to improve the same biomarkers in hamsters [40] and humans [41] . Many studies in rodents [10] [11] [12] [42] [43] [44] showed that dietary di-CLNA supplementation decreases body weight, body fat as well as plasma triglycerides and cholesterol. This study speculates that because mono-CLNA has an original structure compared to di-CLNA, this conjugated fatty acid will have improved or equally effective glucose tolerance than CLA or a-linolenic acid alone. None of them combined an n-3 PUFA and a CLA structure. However, dietary supplementation of piglets with mono-CLNA for 14 days did not improve body weight, body fat nor blood lipid profiles. Our findings extend previous studies in rodents which reported that dietary mono-CLNA did not lower body weight [17, 45] . By analogy, dietary di-CLNA isomers did not lower adipose tissue weight as well as total cholesterol and triglycerides in the plasma of animals [12, 17, 44, 46, 47] and humans [48] .
Liver fatty acid composition CLNA and CLA concentrations in liver reflected the dietary intake of these fatty acids. This response suggests that a 2-week supplementation was sufficient for stabilization of PUFA status within the piglet's body. Our results are in line with Chartrand et al. [49] who reported that dietary fatty acid content consumed for at least 14 days was proportional to plasma fatty acid profiles and remained constant up to study completion at 36 days. According to Riccardi et al. [50] , the modification of tissue fatty acids profile could potentially change insulin sensitivity through several mechanisms including receptor binding and affinity.
Our results also showed that giving mono-CLNA to piglets changed the n-3 and n-6 fatty acid balance. More specifically, compared to the W3 diet, feeding mono-CLNA for 2 weeks decreased the proportions of 18:3n-3, 20:3n-3, 20:5n-3, 22:5n-3 together with an increase in 20:4n-6 and total n-6 PUFA content. Since a previous study in mice reported that n-3 PUFA chronic depletion in the liver led to the development of hepatic insulin resistance over a 3-month period [51] , further studies need to be carried out for an extended period of time in pigs fed CLNA with additional health indicators (blood biochemical, other tissue lipid profile, etc.) in order to better assess the safety aspects of consuming dietary mono-CLNA isomers.
Glucose tolerance
One of our hypotheses was that combining a conjugated and an n-3 PUFA structure in one fatty acid, like mono-CLNA, would improve insulin sensitivity considering that dietary CLA seems to lower insulinemia in rats [52] and a-linolenic acid intake seems to reduce insulin resistance in rats [53] and in humans [54] .
Our results suggest a significant treatment effect for fasting insulin concentration and insulin sensitivity on the OGTT day (p = 0.03). However, we consider that this result is unlikely of biological significance because specific a priori contrasts indicate that there is no treatment effect of mono-CLNA diet compared to the three other dietary groups. Moreover, these differences were not confirmed at the day of IVGTT or during the two glucose tolerance tests. One possible explanation could be a higher insulin secretion generated by environmental/psychological stresses during the first experiment, i.e., human presence, handling, noise, etc. [55, 56] . Also, no treatment effect was seen on C-peptide, a good indicator of endogenous insulin secretion [57] , either for OGTT or IVGTT. In regard to the different indexes of insulin sensitivity (HOMA2-%S, ISI Matsuda and SI) and insulin secretion (Insulin and C-peptide levels, AUCs and HOMA2-%B), none were improved by ingestion of mono-CLNA for 2 weeks.
Results on a closer structural analog to mono-CLNA such as di-CLNA showed some inconsistency. Indeed, although several studies reported that dietary supplementation with di-CLNA isomers can decrease type 2 diabetes risk [12] and improve glucose tolerance [9, 58] in mice, others reported an increase in insulin resistance (HOMA-IR index) in rats [46] similar to what is reported in mice [59, 60] , pigs [61] , and humans [62] . Moreover, most of the studies using n-3 PUFA supplement in humans failed to improve insulin sensitivity [63, 64] .
Limitations of the present study
The present study extends previous findings [9, 42, 46, 58] using a neonatal pig model and randomized experimental design to compare mono-CLNA diet versus three other dietary treatments (CLA, W3, and W6). Nevertheless, it has some limitations including the duration of the supplementation and the composition of the CLA diet, since we used a mixture of two isomers: c9-t11-18:3 ? t10-c12-18:3. Even if most previous studies have used a CLA isomer mixture, recent findings show that purified CLA isomers could have opposite actions on glucose tolerance, with t10-c12-18:3 reducing insulin sensitivity and c9-t11-18:3 enhancing insulin tolerance [3] . Mono-CLNA was also a mixture of two isomers and this is mostly because it is not possible to cost effectively separate the two CLNA isomers for generating high doses of single CLNA isomers for feeding animals. Therefore, a direct comparison between CLA and CLNA diets based only on the chemical structure is limited.
Conclusions
This study showed that mono-CLNA, combining conjugated and an n-3 double-bond structure, did not provide additive improvement for body composition, glucose tolerance, or blood lipid profile in the neonatal piglet model supplemented for a period of 2 weeks. Conversely, mono-CLNA decreased total n-3 PUFA in liver, a finding which merits consideration in regard to neonatal development and safety.
